Indication assessment · §3
Adjunctive therapy in type 1 diabetes — trial records
Trial records in the Institute's register bearing on adjunctive therapy in type 1 diabetes.
§3Trials in this indication
15 trial records in the Institute's register bear on this indication, of which 3 are published trials.
Table 2. Trial records bearing on adjunctive therapy in type 1 diabetes.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| ADJUNCT-ONE | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | 1,398 | 2016 |
| ADJUNCT-TWO | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | 835 | 2016 |
| PRAM-T1D-PIVOTAL | Pramlintide | Phase 3 | Randomised, double-blind, placebo-controlled | 480 | 2002 |
| ADJUNCT-ONE-REGIONAL-CNprogramme record | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2016 |
| ADJUNCT-TWO-ADHERENCEprogramme record | Liraglutide | Phase 3 | Observational | — | 2016 |
| PRAM-T1D-PIVOTAL-ADHERENCEprogramme record | Pramlintide | Phase 3 | Observational | — | 2002 |
| ADJUNCT-ONE-QOLprogramme record | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2016 |
| ADJUNCT-TWO-BIOMARKERprogramme record | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2016 |
| PRAM-T1D-PIVOTAL-BIOMARKERprogramme record | Pramlintide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2002 |
| ADJUNCT-ONE-BODY-COMPprogramme record | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2016 |
| ADJUNCT-TWO-ELDERLYprogramme record | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2016 |
| PRAM-T1D-PIVOTAL-ELDERLYprogramme record | Pramlintide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2002 |
| ADJUNCT-ONE-REGIONAL-JPprogramme record | Liraglutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2016 |
| ADJUNCT-TWO-OLEprogramme record | Liraglutide | Phase 3 | Single-arm open-label | — | 2016 |
| PRAM-T1D-PIVOTAL-OLEprogramme record | Pramlintide | Phase 3 | Single-arm open-label | — | 2002 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-12/3 · https://compoundevidence.com/indications/t1dm-adjunct/trials/ · retrieved 30 July 2026